]>
IRCT20211125053177N1 IRCT 2022-05-05 Kerman University of Medical Sciences Comparison of the effect of Commiphora mukul and mefenamic acid on abnormal mensural bleeding Comparison of the effect of Commiphora mukul capsule and mefenamic acid on menorrhagia: A-triple-blind randomized clinical trial 2022-07-11 anticipated 60 Complete https://irct.ir/trial/60546 interventional Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Assignment of patients to the two groups is done using the randomized block method in 4 blocks. Random random block table for two groups using R software is prepared as follows: B A A A A B A A B B A A B B B B B A A B B A A A B B A B B A B B A A B B A B A B A A B A A B B A A A B B B B A B A A B A, Blinding description: The capsule containing the Commiphora mukul extract will be very similar in appearance to the mefenamic acid capsule, the packaging of the drugs is the same and coded, and the way both drugs are used is the same. The patient, physician, and statistician do not know which drug each code belongs to. 3 menorrhagia. Intervention 1: The first intervention group receives a 250 g capsule containing commiphora mukul powder every 8 hours every month from the first to the fifth day of menstrual bleeding for 3 consecutive months. Intervention 2: The second intervention group receives a 250 g capsule of mefenamic acid every 8 hours every month from the first to the fifth day of menstrual bleeding for 3 consecutive months. Yes - There is a plan to make this available What will be shared: Study data is published with confidentiality. When: After publishing the article To whom: The data is accessible to all researchers. Conditions: The analyzed data can be used only by mentioning the source. Where to obtain: scientific respondent of the study How to obtain: The study data can be received through the e-mail of the scientific respondent of the study Comments:
public Asma Ahmadzadeh Heshmati
Unit One, Second Apartment on the left (Golshan Apartment), NO.8, Neshat Park
Kerman Iran (Islamic Republic of) 7613648443 +98 34 3253 2275 a.ahmadzade1388@yahoo.com Kerman University of Medical Sciences scientific Asma Ahmadzadeh Heshmati
Unit One, Second Apartment on the left (Golshan Apartment), NO.8, Neshat Park
Kerman Iran (Islamic Republic of) 7613648443 +98 34 3253 2275 a.ahmadzade1388@yahoo.com Kerman University of Medical Sciences Iran (Islamic Republic of) Menorrhagia no history of known systemic or inflammatory pelvic diseases not pregnant Do not take certain medications not having a Pap smear and abnormal ultrasound not having a history of allergies to herbs 15 years 55 years Female N92.0 Excessive and frequent menstruation with regular cycle Treatment - Drugs Treatment - Drugs The first intervention group receives a 250 g capsule containing commiphora mukul powder every 8 hours every month from the first to the fifth day of menstrual bleeding for 3 consecutive months. The second intervention group receives a 250 g capsule of mefenamic acid every 8 hours every month from the first to the fifth day of menstrual bleeding for 3 consecutive months. Menstrual bleeding volume and number of bleeding days based on Pictorial blood loss assessment chart (PBLAC)Hemoglobin level in CBC (Complete Blood Count) test. Timepoint: The seventh day of each cycle and if bleeding continues, the evaluation is done every week for up to three cycles. Method of measurement: Pictorial blood loss assessment chart (PBLAC), CBC (Complete Blood Count) laboratory test. Quality of Life. Timepoint: Beginning and end of the study (after the end of the third menstrual cycle). Method of measurement: MQ Questionnaire. Kerman University of Medical Sciences Approved 2022-03-08 Ethics Committee of Kerman University of Medical Sciences Kerman University of Medical Sciences campus, the beginning of Haft Bagh Alavi axis Kerman Kerman Iran (Islamic Republic of)